Cohance Lifesciences Limited (BOM:543064)

Market Cap	148.00B
Revenue (ttm)	12.11B
Net Income (ttm)	1.77B
Shares Out	n/a
EPS (ttm)	6.88
PE Ratio	83.62
Forward PE	30.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,061
Average Volume	24,270
Open	384.30
Previous Close	384.20
Day's Range	379.35 - 397.00
52-Week Range	379.35 - 1,328.20
Beta	n/a
RSI	9.28
Earnings Date	Feb 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.